Lipoprotein changes in women taking low-dose combined oral contraceptive pills: A cross-sectional study in Basra, Iraq;Modification des taux de lipoprotéines chez les femmes sous contraceptifs oraux associés faiblement dosés: Une étude transversale réalisée à Bassora (Iraq)

Eastern Mediterranean Health Journal

Volumn 17, Issue 9, 2011, Pages 684-688

  Abdel Barry, J A ^a   Flaf, M S ^a   Al Namaa, L M ^a   Hassan, N A ^a  

^a UNIVERSITY OF BASRAH   (Iraq)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DOSE ORAL CONTRACEPTIVE; MICROGNON; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADOLESCENT; ADULT; AGE; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; IRAQ; LIPID ANALYSIS; LOW DRUG DOSE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 80052739260     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: 10.26719/2011.17.9.684     Document Type: Article

References (18)

1. Glasier A. Contraception. In: Edmonds DK, ed. Dewhurst's textbook of obstetrics and gynaecology for postgraduates, 6th ed. London, Blackwell Science, 1999:374.
2. Guillebaud J. Contraception: your questions answered, 2nd ed. Edinburgh, Churchill Livingstone, 1993.
3. Burkman RT et al. Current perspectives on oral contraceptive use. American Journal of Obstetrics and Gynecology, 2001, 185(2 Suppl.):S4-12.
4. Hatcher RA et al. The essentials of contraceptive technology. Baltimore, Johns Hopkins School of Public Health, Population Information Program, 1997:1-28.
5. Moore JG. Contraception and sterilization. In: Hacker NF, Moore JG, eds. Essentials of obstetrics and gynecology, 2nd ed. Philadelphia, WB Saunders Company, 1992:453-467.
6. Fotherby K. Twelve years of clinical experience with an oral contraceptive containing 30 micrograms ethinyloestradiol and 150 micrograms desogestrel. Contraception, 1995, 51:3-12.
7. Warren MP. Metabolic effects of contraceptive steroids. American Journal of the Medical Sciences, 1973, 265:4-21.
8. Nash AL, Cornish EJ, Hain R. Metabolic effects of oral contraceptives containing 30 micrograms and 50 micrograms of oestrogen. Medical Journal of Australia, 1979, 2:277-281.
9. Straznicky NE et al. A study of the interactive effects of oral contraceptive use and dietary fat intake on blood pressure, cardiovascular reactivity and glucose tolerance in normoten-sive women. Journal of Hypertension, 1998, 16:357-368.
10. Akerlund M. Clinical experience of a combined oral contraceptive with very low dose ethinyl estradiol. Acta Obstetricia et Gynecologica Scandinavica. Supplement, 1997, 164:63-65.
11. Cong KJ, Wang TT, Liu GR. Lipid metabolism and pregnancy induced hypertension. Zhonghua Fu Chan Ke Za Zhi, 1994, 29(11):561-563, 697-698.
12. Kasule J et al. Evaluation of combined oral contraceptive pill in black Zimbabwean women. Central African Journal of Medicine, 1999, 37:403-409.
13. Esrobar-Morreal H, Lasuncien M, Sancho J. Treatment of hir-sutism with ethinyl estradiol contraceptive pills. Fertility and Sterility, 2000, 74:816-819.
14. Chen JK et al. A pharmacodynamic and pharmacokinetic study of the Chinese No. 1 pill. Contraception, 1990, 42:439-453.
15. nd ed. Philadelphia, WB Saunders Company, 1994:1002-1093.
16. Karjalainen A et al. Mechanisms regulating LDL metabolism in subjects on peroral and transdermal estrogen replacement therapy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20:1101-1106.
17. Mintzer M. Contraception. In: Sloane PD, Slatt LM, Baker RM, eds. Essentials of family medicine. Baltimore, Williams and Wilkins, 1988:175-176.
18. Leridon H. Fertility and contraception in 12 developed countries. Family Planning Perspectives, 1981, 13:93-102.